
Category
Subgroup
CT + BEV better
CT better
HR
95% CI
All
All (N = 2591)
0.94
0.75–1.18
Age, years
<40 (N = 484)
0.88
0.51–1.54
40–<65 (N = 1868)
0.89
0.68–1.17
≥65 (N = 239)
1.50
0.73–3.05
Baseline ECOG PS
0 (N = 2388)
0.98
0.77–1.25
1 (N = 192)
0.68
0.31–1.49
Region
Australia/W & N Europe/US/Canada (N = 1575)
0.99
0.74–1.34
C & S Europe/Israel/Russia (N = 308)
1.37
0.74–2.54
South America (N = 59)
1.44
0.39–5.37
Asia/New Zealand/South Africa (N = 649)
0.66
0.42–1.05
Race
Asian (N = 613)
0.70
0.43–1.15
Black (N = 61)
1.64
0.27–9.84
Other (N = 17)
1.67
0.25–11.16
White (N = 1900)
1.00
0.77–1.31
Menopausal status
Post (N = 1250)
1.16
0.83–1.62
Pre (N = 1341)
0.79
0.58–1.08
Tumor size, cm
0–<2 (N = 939)
1.17
0.69–1.98
≥2–5 (N = 1514)
0.93
0.70–1.23
≥5 (N = 132)
0.84
0.45–1.58
No. of positive lymph nodes
0 (N = 1640)
0.79
0.56–1.13
1–3 (N = 638)
1.01
0.65–1.56
≥4 (N = 313)
1.14
0.75–1.73
Adjuvant CT
Anthracycline (N = 947)
0.83
0.54–1.28
Anthracycline + taxane (N = 1508)
1.03
0.78–1.37
Taxane (N = 136)
0.63
0.24–1.66
Hormone receptor status
ER and PgR negative (N = 2453)
0.93
0.73–1.17
ER and/or PgR low (N = 138)
1.42
0.46–4.34
Surgery
Breast-conserving surgery (N = 1644)
0.93
0.67–1.30
Mastectomy (N = 947)
0.95
0.69–1.31
0.2
0.5
1
2
5
HR (95% CI)